Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
p107 CRISPR/Cas9 KO Plasmid (m): sc-422614
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- p107 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the p107 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: p107 Antibody (SD9): sc-250
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
p107 CRISPR/Cas9 KO Plasmid (m) | sc-422614 | 20 µg | $397.00 |
Overview
Mouse Rbl1 encodes the retinoblastoma family protein p107, a cell cycle regulator that restrains G1/S progression by binding E2F transcription factors and coordinating cyclin-dependent kinase signaling. p107 integrates mitogenic cues with transcriptional control of DNA replication and S-phase entry, and it contributes to checkpoint enforcement and cellular differentiation programs. As part of the RB pathway, p107 function intersects with pRB/p130 networks to modulate chromatin-associated repression and proliferation decisions. Dysregulation of RB-family control and E2F activity is broadly relevant to oncogenic transformation models and to studies of aberrant proliferation and lineage commitment in mammalian tissues.
p107 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Rbl1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Rbl1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Rbl1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish p107 protein expression.
This CRISPR knockout system enables efficient generation of Rbl1-deficient cell models for investigation of p107 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Rbl1 exon(s) critical for p107 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Rbl1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by p107 CRISPR/Cas9 KO Plasmid (m) and p107 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Rbl1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by p107 HDR Plasmid (m) and p107 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Rbl1 homology arms to support homology-directed repair at defined Rbl1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.